Ubs Asset Management Americas Inc United Therapeutics Corp Transaction History

Ubs Asset Management Americas Inc

  • $381 Billion
  • Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in United Therapeutics Corp stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 212,657 shares of UTHR stock, worth $76.1 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
212,657
Previous 243,955 12.83%
Holding current value
$76.1 Million
Previous $77.7 Million 1.94%
% of portfolio
0.02%
Previous 0.02%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$311.04 - $363.55 $9.73 Million - $11.4 Million
-31,298 Reduced 12.83%
212,657 $76.2 Million
Q2 2024

Aug 13, 2024
BUY
$228.26 - $319.04 $18.1 Million - $25.3 Million
79,333 Added 48.19%
243,955 $77.7 Million
Q1 2024

May 15, 2024
BUY
$210.76 - $249.51 $254,387 - $301,158
1,207 Added 0.74%
164,622 $37.8 Million
Q4 2023

Feb 14, 2024
BUY
$214.88 - $256.94 $2.15 Million - $2.57 Million
9,999 Added 6.52%
163,415 $35.9 Million
Q3 2023

Nov 13, 2023
BUY
$211.82 - $248.24 $10.5 Million - $12.3 Million
49,440 Added 47.55%
153,416 $34.7 Million
Q1 2023

May 15, 2023
BUY
$212.99 - $276.17 $4.76 Million - $6.17 Million
22,349 Added 27.38%
103,976 $23.3 Million
Q4 2022

Feb 14, 2023
BUY
$205.95 - $280.43 $345,790 - $470,841
1,679 Added 2.1%
81,627 $22.7 Million
Q3 2022

Nov 14, 2022
SELL
$203.3 - $244.17 $835,969 - $1 Million
-4,112 Reduced 4.89%
79,948 $16.7 Million
Q2 2022

Aug 12, 2022
SELL
$174.81 - $241.14 $1.06 Million - $1.46 Million
-6,055 Reduced 6.72%
84,060 $19.8 Million
Q1 2022

May 16, 2022
BUY
$166.16 - $213.96 $463,752 - $597,162
2,791 Added 3.2%
90,115 $16.2 Million
Q4 2021

Feb 14, 2022
SELL
$184.32 - $216.08 $1.46 Million - $1.71 Million
-7,923 Reduced 8.32%
87,324 $18.9 Million
Q3 2021

Nov 15, 2021
BUY
$179.86 - $214.88 $446,952 - $533,976
2,485 Added 2.68%
95,247 $17.6 Million
Q2 2021

Aug 16, 2021
SELL
$170.47 - $211.93 $3.74 Million - $4.66 Million
-21,968 Reduced 19.15%
92,762 $16.6 Million
Q1 2021

May 14, 2021
SELL
$153.94 - $174.85 $46,951 - $53,329
-305 Reduced 0.27%
114,730 $19.2 Million
Q4 2020

Mar 01, 2021
BUY
$101.87 - $151.79 $724,906 - $1.08 Million
7,116 Added 6.59%
115,035 $17.5 Million
Q3 2020

Nov 13, 2020
SELL
$99.9 - $121.13 $61,738 - $74,858
-618 Reduced 0.57%
107,919 $10.9 Million
Q2 2020

Aug 14, 2020
SELL
$92.74 - $125.82 $470,377 - $638,159
-5,072 Reduced 4.46%
108,537 $13.1 Million
Q1 2020

May 15, 2020
BUY
$79.39 - $115.35 $880,117 - $1.28 Million
11,086 Added 10.81%
113,609 $10.8 Million
Q4 2019

Feb 14, 2020
BUY
$78.31 - $95.34 $3.61 Million - $4.4 Million
46,100 Added 81.7%
102,523 $9.03 Million
Q3 2019

Nov 14, 2019
SELL
$74.85 - $85.99 $117,065 - $134,488
-1,564 Reduced 2.7%
56,423 $4.5 Million
Q2 2019

Aug 15, 2019
SELL
$76.06 - $120.81 $17 Million - $27 Million
-223,761 Reduced 79.42%
57,987 $0
Q1 2019

May 14, 2019
BUY
$107.15 - $126.84 $13.5 Million - $16 Million
126,081 Added 80.99%
281,748 $0
Q4 2018

Feb 13, 2019
SELL
$101.4 - $128.73 $102,312 - $129,888
-1,009 Reduced 0.64%
155,667 $17 Million
Q3 2018

Nov 14, 2018
BUY
$113.81 - $129.46 $1.59 Million - $1.81 Million
13,983 Added 9.8%
156,676 $0
Q2 2018

Aug 14, 2018
BUY
$101.14 - $118.31 $1.32 Million - $1.55 Million
13,092 Added 10.1%
142,693 $0
Q1 2018

May 14, 2018
BUY
$107.21 - $151.94 $1.09 Million - $1.54 Million
10,152 Added 8.5%
129,601 $0
Q4 2017

Feb 09, 2018
SELL
$118.58 - $151.28 $627,051 - $799,968
-5,288 Reduced 4.24%
119,449 $0
Q3 2017

Nov 13, 2017
BUY
$114.6 - $136.81 $14.3 Million - $17.1 Million
124,737
124,737 $0

Others Institutions Holding UTHR

# of Institutions
671
Shares Held
42.3M
Call Options Held
194K
Put Options Held
295K
View Full List

About UNITED THERAPEUTICS Corp

UTHR Quotes by TradingView
  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $16.3B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email